|
- Treatment for HER2-Negative Advanced Breast Cancer - WebMD
If your breast cancer is HER2-negative and advanced, what are your treatment options? Learn how hormonal therapies, chemotherapy, targeted therapies, and immunotherapy may help you
- HER2-Negative Breast Cancer: Meaning Treatment
HER2-negative breast cancer involves having cancerous cells in your breast that don’t contain high levels of the protein human epidermal growth factor 2 (HER2) With most breast cancers, hormones and or the HER2 protein fuel cancer growth For example, with HER2-positive breast cancer, excess HER2 leads to cancerous tumors
- Treatment of Stage IV (Metastatic) Breast Cancer
Women with stage IV breast cancer are most often treated with hormone therapy, chemotherapy, targeted therapy, immunotherapy, or some combination of these Surgery or radiation might be used to help prevent or treat symptoms
- Treatment for hormone receptor-positive, HER2-negative advanced breast . . .
ET alone or in combination with targeted for metastatic hormone receptor-positive, HER2-negative breast cancer is presented here The treatment of HER2-positive disease is discussed elsewhere, as is chemotherapy for ET-resistant, metastatic hormone receptor-positive breast cancer
- NCCN Guidelines Updates: Management of Patients With HER2-Negative . . .
Treatment for metastatic HER2-negative breast cancer is becoming increasingly individualized as more of the tumor landscape is described and drugs are developed to target its pathways Survival can be prolonged by CDK4 6 inhibitors in patients with hormone receptor–positive tumors and by immunotherapy in those with triple-negative disease In patients with BRCA1 2 mutations, PARP inhibitors
- Treatment of Breast Cancer by Stage - NCI
The stage of breast cancer is an important factor in determining which type of treatment may work best for you Learn more about treatment options for breast cancer by stage
- Expert consensus on treating HR+ HER2- metastatic breast cancer based . . .
Hormone receptor-positive, HER2-negative metastatic breast cancer (HR+ HER2-mBC) is incurable, but recent progress has been made in developing new treatment options and the treatment landscape is rapidly shifting There are published recommendations for treatment choices and sequencing to help guide oncologists in treating HR+ HER2-mBC, but little evidence has been published regarding real
- Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 . . . - BioSpace
About ORSERDU (elacestrant) U S Indication: ORSERDU (elacestrant), 345 mg tablets, is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy Full prescribing
|
|
|